Snack sales are on the decline, Wegovy prices now lower for cash buyers, Lilly beats Novo to Indian market, Novo spends $200M to license "triple agonist" drug, and more!
Share this post
The Gut Punch Weekly #13
Share this post
Snack sales are on the decline, Wegovy prices now lower for cash buyers, Lilly beats Novo to Indian market, Novo spends $200M to license "triple agonist" drug, and more!